(0.51%) 5 072.25 points
(0.39%) 38 219 points
(0.61%) 17 545 points
(0.72%) $79.57
(1.60%) $1.963
(0.65%) $2 326.10
(0.27%) $26.82
(1.53%) $969.50
(-0.07%) $0.932
(-0.09%) $11.02
(-0.08%) $0.798
(-0.67%) $92.64
5 days till quarter result
(bmo 2024-05-07)
Expected move: +/- 11.59%
@ $15.77
Utstedt: 14 feb 2024 @ 20:20
Avkastning: 4.57%
Forrige signal: feb 13 - 21:31
Forrige signal:
Avkastning: 6.45 %
Live Chart Being Loaded With Signals
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States...
Stats | |
---|---|
Dagens volum | 365 232 |
Gjennomsnittsvolum | 378 960 |
Markedsverdi | 721.88M |
EPS | $0 ( 2024-02-29 ) |
Neste inntjeningsdato | ( $-0.120 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -33.65 |
ATR14 | $0.0620 (0.38%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-12 | Tagliaferri Mary | Buy | 27 900 | Stock Option (right to buy) |
2024-03-12 | Tagliaferri Mary | Buy | 4 660 | Common Stock |
2024-02-29 | Tagliaferri Mary | Buy | 0 | |
2024-03-05 | Rajah Vignesh | Sell | 1 711 | Common Stock |
2024-03-05 | Gad Thomas | Sell | 3 900 | Common Stock |
INSIDER POWER |
---|
77.60 |
Last 98 transactions |
Buy: 3 651 211 | Sell: 357 293 |
Volum Korrelasjon
Y-mAbs Therapeutics, Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
MAGS | 0.928 |
IMUX | 0.912 |
SIEN | 0.897 |
BWAY | 0.89 |
APOP | 0.886 |
MOSY | 0.886 |
CMLF | 0.865 |
IKNX | 0.858 |
THMO | 0.811 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Y-mAbs Therapeutics, Inc Korrelasjon - Valuta/Råvare
Y-mAbs Therapeutics, Inc Økonomi
Annual | 2023 |
Omsetning: | $84.82M |
Bruttogevinst: | $73.40M (86.54 %) |
EPS: | $-0.490 |
FY | 2023 |
Omsetning: | $84.82M |
Bruttogevinst: | $73.40M (86.54 %) |
EPS: | $-0.490 |
FY | 2022 |
Omsetning: | $65.27M |
Bruttogevinst: | $57.70M (88.41 %) |
EPS: | $-2.20 |
FY | 2021 |
Omsetning: | $34.90M |
Bruttogevinst: | $32.38M (92.80 %) |
EPS: | $-1.378 |
Financial Reports:
No articles found.
Y-mAbs Therapeutics, Inc
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.